OCULIS HOLDING AG (OCS) Stock Price & Overview
NASDAQ:OCS • CH1242303498
Current stock price
The current stock price of OCS is 24.69 USD. Today OCS is down by -1.2%. In the past month the price decreased by -16.05%. In the past year, price increased by 28.73%.
OCS Key Statistics
- Market Cap
- 1.259B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.41
- Dividend Yield
- N/A
OCS Stock Performance
OCS Stock Chart
OCS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to OCS. When comparing the yearly performance of all stocks, OCS is one of the better performing stocks in the market, outperforming 85.75% of all stocks.
OCS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCS. The financial health of OCS is average, but there are quite some concerns on its profitability.
OCS Earnings
On March 3, 2026 OCS reported an EPS of -0.42 and a revenue of 411.00K. The company beat EPS expectations (1.62% surprise) and beat revenue expectations (210.28% surprise).
OCS Forecast & Estimates
15 analysts have analysed OCS and the average price target is 48.14 USD. This implies a price increase of 94.99% is expected in the next year compared to the current price of 24.69.
For the next year, analysts expect an EPS growth of 1.43% and a revenue growth 763.81% for OCS
OCS Groups
Sector & Classification
OCS Financial Highlights
Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 8.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.94% | ||
| ROE | -50.47% | ||
| Debt/Equity | 0.01 |
OCS Ownership
OCS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.12 | 828.496B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 579.15B | ||
| MRK | MERCK & CO. INC. | 23.12 | 295.772B | ||
| PFE | PFIZER INC | 9.06 | 153.813B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.24 | 119.215B | ||
| ZTS | ZOETIS INC | 16.01 | 47.848B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.97 | 26.738B | ||
| VTRS | VIATRIS INC | 5.2 | 15.026B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.997B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.705B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.62B | ||
| CORT | CORCEPT THERAPEUTICS INC | 45.51 | 4B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCS
Company Profile
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Company Info
IPO: 2023-03-03
OCULIS HOLDING AG
Bahnhofstrasse 20
Zug ZUG CH
Employees: 60
Phone: 41417113960
OCULIS HOLDING AG / OCS FAQ
Can you describe the business of OCULIS HOLDING AG?
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Can you provide the latest stock price for OCULIS HOLDING AG?
The current stock price of OCS is 24.69 USD. The price decreased by -1.2% in the last trading session.
What is the dividend status of OCULIS HOLDING AG?
OCS does not pay a dividend.
How is the ChartMill rating for OCULIS HOLDING AG?
OCS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is OCS stock listed?
OCS stock is listed on the Nasdaq exchange.
What is OCULIS HOLDING AG worth?
OCULIS HOLDING AG (OCS) has a market capitalization of 1.26B USD. This makes OCS a Small Cap stock.
Who owns OCULIS HOLDING AG?
You can find the ownership structure of OCULIS HOLDING AG (OCS) on the Ownership tab.